Ignite Creation Date:
2025-12-25 @ 3:37 AM
Ignite Modification Date:
2025-12-26 @ 2:21 AM
Study NCT ID:
NCT05491902
Status:
TERMINATED
Last Update Posted:
2022-08-08
First Post:
2021-09-28
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Pilot PET Study of Regional Cerebral Protein Synthesis in Alzheimer's
Sponsor:
University of Manchester
Organization:
Study Overview
Official Title:
Pilot PET Study of Regional Cerebral Protein Synthesis in Alzheimer's
Status:
TERMINATED
Status Verified Date:
2022-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
11C-leucine no longer available at Wolfson Molecular Imaging Centre (after suspension of recruitment due to COVID pandemic)
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Measuring the rate of cerebral protein synthesis (rCPS) may enable us to better-understand the progression of Alzheimer's Disease (AD). This study is using a new method of measuring rCPS non-invasively, and to offer new approaches to the assessment of new therapeutic strategies in clinical trials.
Previous studies have established the utility of \[11C\]-Leucine PET to assess the rCPS. This study will use \[11C\]- Leucine PET to measure rCPS in AD patients versus age-matched and young healthy subjects to determine whether a measurable difference exists.
The study will involve participants receiving up to two PET scans, a structural MRI scan. The PET scanning procedures will involve some withdrawal of blood samples.
The ultimate goal of this proposal is to indicate new routes for treatment of AD.
Previous studies have established the utility of \[11C\]-Leucine PET to assess the rCPS. This study will use \[11C\]- Leucine PET to measure rCPS in AD patients versus age-matched and young healthy subjects to determine whether a measurable difference exists.
The study will involve participants receiving up to two PET scans, a structural MRI scan. The PET scanning procedures will involve some withdrawal of blood samples.
The ultimate goal of this proposal is to indicate new routes for treatment of AD.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: